Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over ...

Walmart has agreed to pay $10 million to settle a U.S. Federal Trade Commission civil lawsuit accusing the world's largest ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Experts said that the novel combination of a GLP-1 and amylin analogue will help obese patients with and without diabetes ...

Results from the Phase III REDEFINE 1 trial show that CagriSema led to a 22.7% mean weight reduction at 68 weeks in adults ...

Novo Nordisk A/S’s next-generation obesity shot CagriSema helped patients lose weight in large studies despite only about ...

Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

We came across a bullish thesis on Novo Nordisk A/S on Kontra Investments’ Substack by Kontra. In this article, we will ...

Additionally, a supportive secondary analysis showed that 50.7% of participants with obesity treated with CagriSema reached non-obesity levels (BMI 30 kg/m²) by the end of treatment, down from a mean ...

Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...

Novo Nordisk has presented full Phase 3 trial results for CagriSema, an experimental weight-loss drug, revealing primarily ...